[go: up one dir, main page]

WO2014014819A3 - Methods of treating glucose metabolism disorders - Google Patents

Methods of treating glucose metabolism disorders Download PDF

Info

Publication number
WO2014014819A3
WO2014014819A3 PCT/US2013/050485 US2013050485W WO2014014819A3 WO 2014014819 A3 WO2014014819 A3 WO 2014014819A3 US 2013050485 W US2013050485 W US 2013050485W WO 2014014819 A3 WO2014014819 A3 WO 2014014819A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
glucose metabolism
metabolism disorders
treating glucose
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/050485
Other languages
French (fr)
Other versions
WO2014014819A2 (en
Inventor
Daniel David Kaplan
Maziyar SABERI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Publication of WO2014014819A2 publication Critical patent/WO2014014819A2/en
Publication of WO2014014819A3 publication Critical patent/WO2014014819A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating individuals with a glucose metablism disorder, and compositions suitable for use in the methods, are provided. The agents and compositions can be used for the treatment and/or prevention of diabetes, insulin resistance, decreased insulin production, hyperglycemia, and metabolic syndrome. Agents of the present invention ar referred to as modulators.
PCT/US2013/050485 2012-07-17 2013-07-15 Methods of treating glucose metabolism disorders Ceased WO2014014819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672690P 2012-07-17 2012-07-17
US61/672,690 2012-07-17

Publications (2)

Publication Number Publication Date
WO2014014819A2 WO2014014819A2 (en) 2014-01-23
WO2014014819A3 true WO2014014819A3 (en) 2014-04-24

Family

ID=49949350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/050485 Ceased WO2014014819A2 (en) 2012-07-17 2013-07-15 Methods of treating glucose metabolism disorders

Country Status (1)

Country Link
WO (1) WO2014014819A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016347688A1 (en) * 2015-10-30 2018-06-21 The University Of Melbourne Methods and compositions for improving glucose metabolism
JP7136468B2 (en) * 2016-11-08 2022-09-13 ユニバーシティ オブ マイアミ Anti-Secretogranin III (SCG3) Antibodies and Uses Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100239589A1 (en) * 2009-02-23 2010-09-23 Salk Institute For Biological Studies Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100239589A1 (en) * 2009-02-23 2010-09-23 Salk Institute For Biological Studies Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof

Also Published As

Publication number Publication date
WO2014014819A2 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
HK1211231A1 (en) Exendin-4 derivatives
WO2014120619A3 (en) Compositions and methods of use in treating metabolic disorders
MX2013009948A (en) Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders.
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
WO2013186240A3 (en) Exendin-4 peptide analogues
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MY176863A (en) Ibat inhibitors for treatment of metabolic disorders and related conditions
ZA201503110B (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
BR112015013046A2 (en) edible composition, method for reducing postprandial blood glucose peak amplitude or glycemic response in a diabetic or non-diabetic person, method for treating a person in need thereof for type 2 diabetes and use of a composition
WO2015106296A8 (en) Enolase 1 (eno1) compositions and uses thereof
WO2012174534A3 (en) Method of treating or ameliorating metabolic disorders using clec-2
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
BR112013030171A2 (en) edible composition, method for reducing peak postprandial blood glucose amplitude or glycemic response in a non-diabetic person, method for treating a person in need of type 2 diabetes treatment, and use of the composition
LT2895477T (en) Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson`s disease.
WO2014014819A3 (en) Methods of treating glucose metabolism disorders
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
EP2533796A4 (en) Methods of treating glucose metabolism disorders
WO2014066400A3 (en) Methods for the effective treatment of metastatic cancer
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
WO2013090319A3 (en) Treatment of type i and type ii diabetes
WO2012173781A3 (en) Methods of treating glucose metabolism disorders
WO2014014816A3 (en) Methods of treating glucose metabolism disorders
WO2014031745A3 (en) Materials and methods for modulating glucose uptake
HK1187552A (en) Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
TN2013000187A1 (en) Pharmaceutical composition, methods for treating and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13820399

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13820399

Country of ref document: EP

Kind code of ref document: A2